Marein Ameliorates Myocardial Fibrosis by Inhibiting HIF-1 α and TGF-β1/Smad2/3 Signaling Pathway in Isoproterenol-stimulated Mice and TGF-β1-stimulated Cardiac Fibroblasts
CONCLUSION: Marein might exert a protective function in isoproterenol-stimulated myocardial fibrotic mice and TGF-β1-stimulated CFs, which might result from the reduction of TGF-β1 induced HIF-1α expression, then inhibiting p-Smad2/3 and Smad2/3 expressions.PMID:38151839 | DOI:10.2174/0113816128282062231218075341 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Guanghao Niu Ying Zhao Huafeng Song Quan Song Xiaoyun Yin Zengyan Zhu Junchi Xu Source Type: research
Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics
CONCLUSION: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.PMID:38151840 | DOI:10.2174/0113816128277350231219062154 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Daniil Sokolov Neha Sharda Aindrila Banerjee Kseniia Denisenko Emad B Basalious Hem Shukla Jaylyn Waddell Nadia M Hamdy Aditi Banerjee Source Type: research
Understanding the Therapeutic Approaches for Neuroprotection
Curr Pharm Des. 2023 Dec 26. doi: 10.2174/0113816128275761231103102125. Online ahead of print.ABSTRACTThe term "neurodegenerative disorders" refers to a group of illnesses in which deterioration of nerve structure and function is a prominent feature. Cognitive capacities such as memory and decision-making deteriorate as a result of neuronal damage. The primary difficulty that remains is safeguarding neurons since they do not proliferate or regenerate spontaneously and are therefore not substituted by the body after they have been damaged. Millions of individuals throughout the world suffer from neurodegenerative diseases. ...
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Nazrana Payal Lalit Sharma Aditi Sharma Yahya Hosan Hobanii Mashael Ahmed Hakami Nemat Ali Summya Rashid Monika Sachdeva Monica Gulati Shivam Yadav Sridevi Chigurupati Abhiav Singh Haroon Khan Tapan Behl Source Type: research
Microbubbles: Revolutionizing Biomedical Applications with Tailored Therapeutic Precision
CONCLUSION: The potential utility of microbubbles in biomedical applications is continually growing as novel formulations and methods. The versatility of microbubbles allows for customization, tailoring the delivery system to various medical applications, including cancer therapy, cardiovascular treatments, and gene therapy.PMID:38151837 | DOI:10.2174/0113816128282478231219044000 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Mohit Kumar Devesh Kumar Shruti Chopra Syed Mahmood Amit Bhatia Source Type: research
Interplay of G-Proteins and Serotonin in the Neuroimmunoinflammatory Model of Chronic Stress and Depression: A Narrative Review
CONCLUSION: The proposed Neuroimmunoinflammatory Stress Model (NIIS Model) suggests that proinflammatory signaling pathways, mediated by metabotropic and ionotropic neurotransmitter receptors, are crucial for maintaining neuronal homeostasis. Chronic mental stress can disrupt this balance, leading to increased pro-inflammatory states in the brain and contributing to neuropsychiatric and psychosomatic disorders, including depression. This model integrates traditional theories on depression pathogenesis, offering a comprehensive understanding of the multifaceted nature of the condition.PMID:38151838 | DOI:10.2174/01138161282...
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Evgenii Gusev Alexey Sarapultsev Source Type: research
Marein Ameliorates Myocardial Fibrosis by Inhibiting HIF-1 α and TGF-β1/Smad2/3 Signaling Pathway in Isoproterenol-stimulated Mice and TGF-β1-stimulated Cardiac Fibroblasts
CONCLUSION: Marein might exert a protective function in isoproterenol-stimulated myocardial fibrotic mice and TGF-β1-stimulated CFs, which might result from the reduction of TGF-β1 induced HIF-1α expression, then inhibiting p-Smad2/3 and Smad2/3 expressions.PMID:38151839 | DOI:10.2174/0113816128282062231218075341 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Guanghao Niu Ying Zhao Huafeng Song Quan Song Xiaoyun Yin Zengyan Zhu Junchi Xu Source Type: research
Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics
CONCLUSION: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.PMID:38151840 | DOI:10.2174/0113816128277350231219062154 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Daniil Sokolov Neha Sharda Aindrila Banerjee Kseniia Denisenko Emad B Basalious Hem Shukla Jaylyn Waddell Nadia M Hamdy Aditi Banerjee Source Type: research
Understanding the Therapeutic Approaches for Neuroprotection
Curr Pharm Des. 2023 Dec 26. doi: 10.2174/0113816128275761231103102125. Online ahead of print.ABSTRACTThe term "neurodegenerative disorders" refers to a group of illnesses in which deterioration of nerve structure and function is a prominent feature. Cognitive capacities such as memory and decision-making deteriorate as a result of neuronal damage. The primary difficulty that remains is safeguarding neurons since they do not proliferate or regenerate spontaneously and are therefore not substituted by the body after they have been damaged. Millions of individuals throughout the world suffer from neurodegenerative diseases. ...
Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Nazrana Payal Lalit Sharma Aditi Sharma Yahya Hosan Hobanii Mashael Ahmed Hakami Nemat Ali Summya Rashid Monika Sachdeva Monica Gulati Shivam Yadav Sridevi Chigurupati Abhiav Singh Haroon Khan Tapan Behl Source Type: research
Privileged Scaffolds in Drug Discovery against Human Epidermal Growth Factor Receptor 2 for Cancer Treatment
Curr Pharm Des. 2023 Dec 21. doi: 10.2174/0113816128283615231218094706. Online ahead of print.ABSTRACTHER2 is the membrane receptor tyrosine kinase showing overexpression in several human malignancies, particularly breast cancer. HER2 overexpression causes the activation of Ras- MAPK and PI3K/Akt/ NF-κB cellular signal transduction pathways that lead to cancer development and progression. HER2 is, therefore, presumed as one of the key targets for the development of tumor-specific therapies. Several preclinical have been developed that function by inhibiting the HER2 tyrosine kinase activity through the prevention of the d...
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Mudasir Nabi Peerzada Rania Hamdy Masood Ahmad Rizvi Saurabh Verma Source Type: research
Breast Cancer-related Lymphedema: Recent Updates on Clinical Efficacy of Therapies and Bioengineering Approaches for a Personalized Therapy
CONCLUSION: As such, currently, a strong foundation for further research into molecular-genetic changes in lymphedema tissue exists, and further research should focus on finding specific targets for personalized treatment through bi-engineering approaches.PMID:38141193 | DOI:10.2174/0113816128269545231218075040 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Xinliang Zhang Narasimha M Beeraka Mikhail Y Sinelnikov Oleg S Glazachev Konstantin S Ternovoy Pengwei Lu Aida Isaeva Yu Cao Jin Zhang Arshia Bakhtiari Nezhad Maria Plotnikova Kuo Chen Source Type: research
Deciphering Potential Role of Hippo Signaling Pathway in Breast Cancer: A Comprehensive Review
Curr Pharm Des. 2023 Dec 21. doi: 10.2174/0113816128274418231215054210. Online ahead of print.ABSTRACTBreast cancer is a heterogeneous disease and a leading malignancy around the world. It is a vital cause of untimely mortality among women. Drug resistance is the major challenge for effective cancer therapeutics. In contrast, cancer stem cells (CSCs) are one of the reasons for drug resistance, tumor progression, and metastasis. The small population of CSCs present in each tumor has the ability of self-renewal, differentiation, and tumorigenicity. CSCs are often identified and enriched using a variety of cell surface marker...
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Hunayna M Bhavnagari Apexa P Raval Franky D Shah Source Type: research
Privileged Scaffolds in Drug Discovery against Human Epidermal Growth Factor Receptor 2 for Cancer Treatment
Curr Pharm Des. 2023 Dec 21. doi: 10.2174/0113816128283615231218094706. Online ahead of print.ABSTRACTHER2 is the membrane receptor tyrosine kinase showing overexpression in several human malignancies, particularly breast cancer. HER2 overexpression causes the activation of Ras- MAPK and PI3K/Akt/ NF-κB cellular signal transduction pathways that lead to cancer development and progression. HER2 is, therefore, presumed as one of the key targets for the development of tumor-specific therapies. Several preclinical have been developed that function by inhibiting the HER2 tyrosine kinase activity through the prevention of the d...
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Mudasir Nabi Peerzada Rania Hamdy Masood Ahmad Rizvi Saurabh Verma Source Type: research
Breast Cancer-related Lymphedema: Recent Updates on Clinical Efficacy of Therapies and Bioengineering Approaches for a Personalized Therapy
CONCLUSION: As such, currently, a strong foundation for further research into molecular-genetic changes in lymphedema tissue exists, and further research should focus on finding specific targets for personalized treatment through bi-engineering approaches.PMID:38141193 | DOI:10.2174/0113816128269545231218075040 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Xinliang Zhang Narasimha M Beeraka Mikhail Y Sinelnikov Oleg S Glazachev Konstantin S Ternovoy Pengwei Lu Aida Isaeva Yu Cao Jin Zhang Arshia Bakhtiari Nezhad Maria Plotnikova Kuo Chen Source Type: research
Deciphering Potential Role of Hippo Signaling Pathway in Breast Cancer: A Comprehensive Review
Curr Pharm Des. 2023 Dec 21. doi: 10.2174/0113816128274418231215054210. Online ahead of print.ABSTRACTBreast cancer is a heterogeneous disease and a leading malignancy around the world. It is a vital cause of untimely mortality among women. Drug resistance is the major challenge for effective cancer therapeutics. In contrast, cancer stem cells (CSCs) are one of the reasons for drug resistance, tumor progression, and metastasis. The small population of CSCs present in each tumor has the ability of self-renewal, differentiation, and tumorigenicity. CSCs are often identified and enriched using a variety of cell surface marker...
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Hunayna M Bhavnagari Apexa P Raval Franky D Shah Source Type: research
Privileged Scaffolds in Drug Discovery against Human Epidermal Growth Factor Receptor 2 for Cancer Treatment
Curr Pharm Des. 2023 Dec 21. doi: 10.2174/0113816128283615231218094706. Online ahead of print.ABSTRACTHER2 is the membrane receptor tyrosine kinase showing overexpression in several human malignancies, particularly breast cancer. HER2 overexpression causes the activation of Ras- MAPK and PI3K/Akt/ NF-κB cellular signal transduction pathways that lead to cancer development and progression. HER2 is, therefore, presumed as one of the key targets for the development of tumor-specific therapies. Several preclinical have been developed that function by inhibiting the HER2 tyrosine kinase activity through the prevention of the d...
Source: Current Pharmaceutical Design - December 23, 2023 Category: Drugs & Pharmacology Authors: Mudasir Nabi Peerzada Rania Hamdy Masood Ahmad Rizvi Saurabh Verma Source Type: research
